| Mrs Megan Diane Przybrowski, PA | |
|
1 Medical Center Dr, Morgantown, WV 26506-1200 | |
| (304) 598-4800 | |
| Not Available |
| Full Name | Mrs Megan Diane Przybrowski |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 11 Years |
| Location | 1 Medical Center Dr, Morgantown, West Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942640297 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| West Virginia University Hospitals | Morgantown, WV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| West Virginia University Medical Corporation | 1052224565 | 1613 |
News Archive
Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, announced that initial data from its large-scale, prospective, multi-center clinical trial were presented today at the 14th International Thyroid Congress, held in Paris, France.
On June 21-23, 2011, the New York Academy of Sciences will bring together physicians, neurologists, clinical neuropsychologists, cellular and molecular biologists and patient advocates to discuss current challenges and potential solutions for improving diagnosis, treatment and management of the cognitive symptoms of MS.
Michael Pulsipher, MD, of the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles, along with Michael Keller, MD from Children's National Health System in Washington, DC, have been awarded $4.8 million by the California Institute for Regenerative Medicine to study the use of a new T-cell therapy to help fight active viral infections in children with severe immune deficiencies.
Under normal conditions, the CHD4 protein is one of the good guys: it stops cells from transcribing faulty DNA, thereby eliminating potential mutation. But in colon cancer and perhaps other kinds of cancer as well, it appears that this protein becomes a kind of double agent, working for the enemy.
It is important to understand the vaccine effectiveness (VE) to determine how much protection it offers to the general population. Unfortunately, only a few studies are available that have determined the effect of the COVID-19 vaccine among the residents of LTCFs.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Megan Diane Przybrowski, PA 867 Blue Goose Rd, Friendsville, MD 21531-1256 Ph: (814) 939-9012 | Mrs Megan Diane Przybrowski, PA 1 Medical Center Dr, Morgantown, WV 26506-1200 Ph: (304) 598-4800 |
News Archive
Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, announced that initial data from its large-scale, prospective, multi-center clinical trial were presented today at the 14th International Thyroid Congress, held in Paris, France.
On June 21-23, 2011, the New York Academy of Sciences will bring together physicians, neurologists, clinical neuropsychologists, cellular and molecular biologists and patient advocates to discuss current challenges and potential solutions for improving diagnosis, treatment and management of the cognitive symptoms of MS.
Michael Pulsipher, MD, of the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles, along with Michael Keller, MD from Children's National Health System in Washington, DC, have been awarded $4.8 million by the California Institute for Regenerative Medicine to study the use of a new T-cell therapy to help fight active viral infections in children with severe immune deficiencies.
Under normal conditions, the CHD4 protein is one of the good guys: it stops cells from transcribing faulty DNA, thereby eliminating potential mutation. But in colon cancer and perhaps other kinds of cancer as well, it appears that this protein becomes a kind of double agent, working for the enemy.
It is important to understand the vaccine effectiveness (VE) to determine how much protection it offers to the general population. Unfortunately, only a few studies are available that have determined the effect of the COVID-19 vaccine among the residents of LTCFs.
› Verified 3 days ago